Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jui-Yi Chen

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Frontiers in Pharmacology|May 29, 2026
Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysisChen-Fu Wen, Min-Hsiang Chuang, Vin-Cent Wu, et al.
Geroscience|May 8, 2026
Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulationYing-Ru Chen, Zheng-Hong Jiang, Jui-Yi Chen, et al.
Cardiovascular Diabetology|July 31, 2024
Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonistsHsuan-Wen Lai, Chun Yin See, Jui-Yi Chen, et al.
Scientific Reports|December 13, 2023
Lower product of magnesium × potassium is associated with higher mortality in chronic hemodialysis patients: a cohort studyJui-Yi Chen, Ming-Yan Jiang, Yun-Ting Huang, et al.
The Journal of Clinical Endocrinology and Metabolism|November 13, 2024
Enhanced Outcomes in Type 2 Diabetes Patients with Acute Kidney Disease Through ThiazolidinedioneLi-Yang Chang, Hung-Wei Liao, Jui-Yi Chen, et al.
Cardiovascular Diabetology|March 8, 2025
Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analysesHsuan-Wen Lai, Jui-Yi Chen, Vin-Cent Wu, et al.
Kidney Research and Clinical Practice|February 5, 2026
Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directionsHeng-Chih Pan, Chung-An Wang, Jui-Yi Chen, et al.
Diabetes Research and Clinical Practice|June 28, 2025
Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapyJui-Yi Chen, Min-Hsiang Chuang, Hsuan-Wen Lai, et al.
International Journal of Molecular Sciences|February 10, 2024
From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney DiseaseTzu-Hsuan Yeh, Kuan-Chieh Tu, Hsien-Yi Wang, et al.
Cardiovascular Diabetology|February 21, 2025
Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipientsLi-Chun Lin, Jui-Yi Chen, Thomas Tao-Min Huang, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Frontiers in Pharmacology|May 29, 2026
Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysisChen-Fu Wen, Min-Hsiang Chuang, Vin-Cent Wu, et al.
Geroscience|May 8, 2026
Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulationYing-Ru Chen, Zheng-Hong Jiang, Jui-Yi Chen, et al.
Cardiovascular Diabetology|July 31, 2024
Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonistsHsuan-Wen Lai, Chun Yin See, Jui-Yi Chen, et al.
Scientific Reports|December 13, 2023
Lower product of magnesium × potassium is associated with higher mortality in chronic hemodialysis patients: a cohort studyJui-Yi Chen, Ming-Yan Jiang, Yun-Ting Huang, et al.
The Journal of Clinical Endocrinology and Metabolism|November 13, 2024
Enhanced Outcomes in Type 2 Diabetes Patients with Acute Kidney Disease Through ThiazolidinedioneLi-Yang Chang, Hung-Wei Liao, Jui-Yi Chen, et al.
Cardiovascular Diabetology|March 8, 2025
Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analysesHsuan-Wen Lai, Jui-Yi Chen, Vin-Cent Wu, et al.
Kidney Research and Clinical Practice|February 5, 2026
Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directionsHeng-Chih Pan, Chung-An Wang, Jui-Yi Chen, et al.
Diabetes Research and Clinical Practice|June 28, 2025
Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapyJui-Yi Chen, Min-Hsiang Chuang, Hsuan-Wen Lai, et al.
International Journal of Molecular Sciences|February 10, 2024
From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney DiseaseTzu-Hsuan Yeh, Kuan-Chieh Tu, Hsien-Yi Wang, et al.
Cardiovascular Diabetology|February 21, 2025
Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipientsLi-Chun Lin, Jui-Yi Chen, Thomas Tao-Min Huang, et al.
Pageof 9